126 related articles for article (PubMed ID: 27237620)
1. Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications.
Simonsen JB
Nanomedicine; 2016 Oct; 12(7):2161-2179. PubMed ID: 27237620
[TBL] [Abstract][Full Text] [Related]
2. Reconstituted HDL as a therapeutic delivery device.
Fox CA; Moschetti A; Ryan RO
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Nov; 1866(11):159025. PubMed ID: 34375767
[TBL] [Abstract][Full Text] [Related]
3. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
4. The Composition of Reconstituted High-Density Lipoproteins (rHDL) Dictates the Degree of rHDL Cargo- and Size-Remodeling via Direct Interactions with Endogenous Lipoproteins.
Pedersbæk D; Kræmer MK; Kempen PJ; Ashley J; Braesch-Andersen S; Andresen TL; Simonsen JB
Bioconjug Chem; 2019 Oct; 30(10):2634-2646. PubMed ID: 31487985
[TBL] [Abstract][Full Text] [Related]
5. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier.
Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M
J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747
[TBL] [Abstract][Full Text] [Related]
6. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.
Lou B; Liao XL; Wu MP; Cheng PF; Yin CY; Fei Z
World J Gastroenterol; 2005 Feb; 11(7):954-9. PubMed ID: 15742395
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits.
Zhang W; Li J; Liu J; Wu Z; Xu Y; Wang J
Pharmazie; 2012 Apr; 67(4):324-30. PubMed ID: 22570939
[TBL] [Abstract][Full Text] [Related]
8. Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing reconstituted HDL as a nanovehicle.
Kim SH; Adhikari BB; Cruz S; Schramm MP; Vinson JA; Narayanaswami V
PLoS One; 2015; 10(8):e0135130. PubMed ID: 26258481
[TBL] [Abstract][Full Text] [Related]
9. Reconstituted high density lipoprotein-based nanoparticles: an overview of applications in regenerative medicine, preparation, evaluation and future trends.
Wang X; Zhou J; Wang W
Curr Pharm Des; 2015; 21(12):1529-44. PubMed ID: 25594411
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins.
Wang J; Jia J; Liu J; He H; Zhang W; Li Z
Drug Deliv; 2013 Nov; 20(8):356-63. PubMed ID: 24079327
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of garcinia glycosides by reconstituted high-density lipoprotein nano-complexes.
Liu C; Zhou Z; Chen Y; Liu J; Wang Y; Liu H
J Microencapsul; 2018 Mar; 35(2):115-120. PubMed ID: 29195484
[TBL] [Abstract][Full Text] [Related]
12. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF).
McConathy WJ; Paranjape S; Mooberry L; Buttreddy S; Nair M; Lacko AG
Drug Deliv Transl Res; 2011 Apr; 1(2):113-20. PubMed ID: 25788110
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E3-mediated cellular uptake of reconstituted high-density lipoprotein bearing core 3, 10, or 17 nm hydrophobic gold nanoparticles.
Chuang ST; Shon YS; Narayanaswami V
Int J Nanomedicine; 2017; 12():8495-8510. PubMed ID: 29225464
[TBL] [Abstract][Full Text] [Related]
14. High-density lipoprotein-biomimetic nanocarriers for glioblastoma-targeting delivery: the effect of shape.
Huang JL; Jiang G; Song QX; Gu X; Song HH; Wang XL; Jiang D; Kang T; Feng XY; Jiang XG; Chen HZ; Gao XL
Pharmazie; 2016 Dec; 71(12):709-714. PubMed ID: 29441999
[TBL] [Abstract][Full Text] [Related]
15. Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism.
Pownall HJ; Rosales C; Gillard BK; Ferrari M
Methodist Debakey Cardiovasc J; 2016 Sep; 12(3):146-150. PubMed ID: 27826368
[TBL] [Abstract][Full Text] [Related]
16. Reconstituted high density lipoprotein (rHDL), a versatile drug delivery nanoplatform for tumor targeted therapy.
Mei Y; Tang L; Xiao Q; Zhang Z; Zhang Z; Zang J; Zhou J; Wang Y; Wang W; Ren M
J Mater Chem B; 2021 Jan; 9(3):612-633. PubMed ID: 33306079
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins.
Zhang W; He H; Liu J; Wang J; Zhang S; Zhang S; Wu Z
Biomaterials; 2013 Jan; 34(1):306-19. PubMed ID: 23069716
[TBL] [Abstract][Full Text] [Related]
18. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model.
Zhang WL; Xiao Y; Liu JP; Wu ZM; Gu X; Xu YM; Lu H
Int J Pharm; 2011 Oct; 419(1-2):314-21. PubMed ID: 21835236
[TBL] [Abstract][Full Text] [Related]
19. Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.
Kornmueller K; Vidakovic I; Prassl R
Molecules; 2019 Aug; 24(15):. PubMed ID: 31382521
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-Loaded Reconstituted High-Density Lipoprotein Prepared by a Novel Dual Centrifugation Approach for Anti-Atherosclerotic Therapy.
Deuringer B; Härdtner C; Krebs K; Thomann R; Holzer M; Hilgendorf I; Süss R
Int J Nanomedicine; 2022; 17():5081-5097. PubMed ID: 36340183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
